As part of assessing the efficacy of using synthesized dual HER2-HSP90 inhibitors in combination therapy for HER2-positive breast cancer, therapeutic pairs consisting of the test compound ATF-2 and standard chemotherapeutic drugs in different concentrations were developed and tested in vitro. Here, ERBB2 is linked to breast cancer.